FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896127985> ?p ?o ?g. }

• W2896127985 endingPage "S569" @default.
• W2896127985 startingPage "S569" @default.
• W2896127985 abstract "PLZ is a next-generation aminoglycoside with structural modifications that protect it from aminoglycoside-modifying enzymes (AMEs) and in vitro activity against multidrug-resistant (MDR) Enterobacteriaceae, including aminoglycoside- and carbapenem-resistant strains. In the CARE study, PLZ was associated with improvement in 28-day all-cause mortality vs. CST in patients with CRE BSI. We report the microbiological outcomes in the CARE study by pathogen and key resistance mechanism. CARE was a multinational, open-label trial that enrolled BSI patients with documented or presumed CRE into two cohorts. Patients in the randomized cohort received PLZ (15 mg/kg q24h IV) or CST (300-mg load [CST base activity] then 5 mg/kg/day IV) plus adjunctive tigecycline or meropenem. Patients in the observational cohort received PLZ plus investigator’s choice of adjunctive agent. Treatment duration was 7–14 days. Isolate identification and susceptibility testing were conducted by a central laboratory. Whole-genome sequencing was used to identify AME and carbapenemase genes. Microbiological outcomes were assessed in patients with confirmed CRE who received ≥1 dose of study drug (mMITT population). Of 45 BSI patients enrolled, 43 had confirmed CRE (mMITT), including Klebsiella pneumoniae (n = 42) and Enterobacter aerogenes (n = 1). Against CRE, PLZ MICs ranged from 0.12 to >128 µg/mL; 25/28 (89.3%) isolates from PLZ-treated patients had a PLZ MIC ≤4 µg/mL, while 3 had a PLZ MIC ≥128 µg/mL and a confirmed 16S ribosomal methyltransferase gene. CST MICs ranged from 0.25 to >128 µg/mL; 6/16 (37.5%) isolates from CST-treated patients had an MIC >2 µg/mL. There were 47 distinct Enterobacteriaceae pathogens isolated from 43 patients, and of these, AME genes were detected in 43/47 (91.5%), most commonly aac(6’)-Ib (n = 29). Carbapenemase genes were detected in 45/47 (95.7%) isolates, most commonly blaKPC (n = 33). PLZ demonstrated higher microbiological eradication rates than CST against CRE, including AME- and carbapenemase-producing isolates (table). The results provide evidence of the efficacy of PLZ-based therapy for patients with BSI due to MDR Enterobacteriaceae, including AME- and carbapenemase-producing organisms. A. W. Serio, Achaogen, Inc.: Employee and Shareholder, Salary. A. Smith, Achaogen, Inc.: Employee and Shareholder, Salary. K. M. Krause, Achaogen, Inc.: Employee, Salary. I. Galani, Achaogen, Inc.: Scientific Advisor, Research funding and honoraria. MSD: Scientific Advisor, Honoraria. A. C. Gales, MSD: Consultant and Speaker, Consulting fee. Pfizer: Consultant and Speaker, Consulting fee. BD: Consultant, Consulting fee. Bayer: Consultant, Consulting fee. A. Jubb, Achaogen, Inc.: Employee and Shareholder, Salary. L. E. Connolly, Achaogen, Inc.: Consultant, Consulting fee." @default.
• W2896127985 created "2018-10-26" @default.
• W2896127985 creator A5003451976 @default.
• W2896127985 creator A5007309318 @default.
• W2896127985 creator A5016309859 @default.
• W2896127985 creator A5039564606 @default.
• W2896127985 creator A5041650561 @default.
• W2896127985 creator A5045620840 @default.
• W2896127985 creator A5059914416 @default.
• W2896127985 date "2018-11-01" @default.
• W2896127985 modified "2023-10-01" @default.
• W2896127985 title "1964. Microbiological Outcomes With Plazomicin (PLZ) vs. Colistin (CST) in Patients With Bloodstream Infections (BSI) Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) in the CARE Study" @default.
• W2896127985 doi "https://doi.org/10.1093/ofid/ofy210.1620" @default.
• W2896127985 hasPublicationYear "2018" @default.
• W2896127985 type Work @default.
• W2896127985 sameAs 2896127985 @default.
• W2896127985 citedByCount "0" @default.
• W2896127985 crossrefType "journal-article" @default.
• W2896127985 hasAuthorship W2896127985A5003451976 @default.
• W2896127985 hasAuthorship W2896127985A5007309318 @default.
• W2896127985 hasAuthorship W2896127985A5016309859 @default.
• W2896127985 hasAuthorship W2896127985A5039564606 @default.
• W2896127985 hasAuthorship W2896127985A5041650561 @default.
• W2896127985 hasAuthorship W2896127985A5045620840 @default.
• W2896127985 hasAuthorship W2896127985A5059914416 @default.
• W2896127985 hasBestOaLocation W28961279851 @default.
• W2896127985 hasConcept C104317684 @default.
• W2896127985 hasConcept C126322002 @default.
• W2896127985 hasConcept C2775992322 @default.
• W2896127985 hasConcept C2776685102 @default.
• W2896127985 hasConcept C2777027569 @default.
• W2896127985 hasConcept C2777058267 @default.
• W2896127985 hasConcept C2779259085 @default.
• W2896127985 hasConcept C2779375183 @default.
• W2896127985 hasConcept C2908647359 @default.
• W2896127985 hasConcept C501593827 @default.
• W2896127985 hasConcept C547475151 @default.
• W2896127985 hasConcept C55493867 @default.
• W2896127985 hasConcept C71924100 @default.
• W2896127985 hasConcept C86803240 @default.
• W2896127985 hasConcept C89423630 @default.
• W2896127985 hasConcept C94665300 @default.
• W2896127985 hasConcept C99454951 @default.
• W2896127985 hasConceptScore W2896127985C104317684 @default.
• W2896127985 hasConceptScore W2896127985C126322002 @default.
• W2896127985 hasConceptScore W2896127985C2775992322 @default.
• W2896127985 hasConceptScore W2896127985C2776685102 @default.
• W2896127985 hasConceptScore W2896127985C2777027569 @default.
• W2896127985 hasConceptScore W2896127985C2777058267 @default.
• W2896127985 hasConceptScore W2896127985C2779259085 @default.
• W2896127985 hasConceptScore W2896127985C2779375183 @default.
• W2896127985 hasConceptScore W2896127985C2908647359 @default.
• W2896127985 hasConceptScore W2896127985C501593827 @default.
• W2896127985 hasConceptScore W2896127985C547475151 @default.
• W2896127985 hasConceptScore W2896127985C55493867 @default.
• W2896127985 hasConceptScore W2896127985C71924100 @default.
• W2896127985 hasConceptScore W2896127985C86803240 @default.
• W2896127985 hasConceptScore W2896127985C89423630 @default.
• W2896127985 hasConceptScore W2896127985C94665300 @default.
• W2896127985 hasConceptScore W2896127985C99454951 @default.
• W2896127985 hasIssue "suppl_1" @default.
• W2896127985 hasLocation W28961279851 @default.
• W2896127985 hasLocation W28961279852 @default.
• W2896127985 hasLocation W28961279853 @default.
• W2896127985 hasOpenAccess W2896127985 @default.
• W2896127985 hasPrimaryLocation W28961279851 @default.
• W2896127985 hasRelatedWork W1567348816 @default.
• W2896127985 hasRelatedWork W1730109376 @default.
• W2896127985 hasRelatedWork W1896132665 @default.
• W2896127985 hasRelatedWork W2092954991 @default.
• W2896127985 hasRelatedWork W3126945909 @default.
• W2896127985 hasRelatedWork W3151407867 @default.
• W2896127985 hasRelatedWork W3173435160 @default.
• W2896127985 hasRelatedWork W3197143332 @default.
• W2896127985 hasRelatedWork W3215674769 @default.
• W2896127985 hasRelatedWork W4308352628 @default.
• W2896127985 hasVolume "5" @default.
• W2896127985 isParatext "false" @default.
• W2896127985 isRetracted "false" @default.
• W2896127985 magId "2896127985" @default.
• W2896127985 workType "article" @default.